PRLD
Prelude Therapeutics Incorporated NASDAQ Listed Sep 25, 2020$4.32
-0.69%
vs $4.35
Mkt Cap $332.5M
52w Low $0.78
74.7% of range
52w High $5.52
50d MA $4.38
200d MA $2.65
P/E (TTM)
-3.4x
EV/EBITDA
—
P/B
4.8x
Debt/Equity
0.3x
ROE
-145.0%
P/FCF
-5.9x
RSI (14)
58.30
ATR (14)
$0.34
Beta
0.71
50d MA
$4.38
200d MA
$2.65
Avg Volume
358.0K
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.
200 Powder Mill Road · Wilmington, DE 19803 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 12, 2026 | BMO | -0.27 | -0.13 | +51.9% | 4.80 | +0.0% | -3.3% | +0.4% | -4.1% | +0.2% | -3.1% | — |
| Mar 10, 2026 | BMO | -0.33 | -0.20 | +39.4% | 3.60 | +3.6% | +5.8% | -11.5% | -2.1% | +1.8% | +2.1% | — |
| Nov 12, 2025 | BMO | -0.35 | -0.26 | +25.7% | 1.47 | +0.7% | +2.7% | +0.7% | +8.6% | +1.8% | -0.6% | — |
| Aug 14, 2025 | BMO | -0.45 | -0.41 | +8.9% | 0.94 | -1.6% | -7.9% | +8.5% | -5.4% | +17.6% | +4.8% | — |
| May 6, 2025 | BMO | -0.47 | -0.42 | +10.6% | 0.80 | +0.3% | -4.0% | +7.0% | -4.5% | +13.0% | +13.3% | — |
| Mar 10, 2025 | BMO | -0.49 | -0.38 | +22.4% | 0.67 | +0.4% | -1.3% | +5.3% | +1.5% | +5.4% | +1.4% | — |
| Nov 6, 2024 | BMO | -0.48 | -0.43 | +10.4% | 1.32 | +0.0% | -3.8% | -6.3% | +0.0% | -3.4% | -7.8% | — |
| Aug 12, 2024 | BMO | -0.46 | -0.46 | +0.0% | 4.75 | -1.1% | +30.5% | -16.8% | +11.8% | -9.7% | +12.7% | — |
| May 7, 2024 | BMO | -0.47 | -0.42 | +10.6% | 3.70 | -0.3% | -3.0% | +13.4% | -8.4% | +1.9% | +1.6% | — |
| Feb 15, 2024 | BMO | -0.50 | -0.47 | +6.0% | 3.48 | +0.6% | +33.0% | -10.2% | -9.1% | +2.4% | +2.3% | — |
| Nov 1, 2023 | BMO | -0.58 | -0.45 | +22.4% | 1.86 | -6.5% | +18.8% | +2.7% | +30.0% | +2.0% | -0.3% | — |
| Aug 3, 2023 | BMO | -0.65 | -0.54 | +16.9% | 3.61 | +2.8% | +1.7% | +0.0% | -2.7% | -0.3% | +1.7% | — |
| May 8, 2023 | AMC | -0.68 | -0.58 | +14.7% | 6.37 | +0.6% | -1.7% | +3.2% | +1.5% | +2.6% | -1.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 4 | D. Boral Capital | Initiates | Buy | $9 | $4.70 | $4.82 | +2.6% | +0.9% | -1.5% | +3.6% | +6.4% | -5.6% |
| Apr 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.70 | $4.92 | +4.7% | -3.8% | -2.9% | -2.7% | +22.5% | -10.1% |
| Mar 11 | Citizens | Maintains | Market Outperform → Market Outperform | — | $3.60 | $3.73 | +3.6% | +5.8% | -11.5% | -2.1% | +1.8% | +2.1% |
| Sep 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.01 | $1.10 | +8.9% | +2.0% | +13.6% | +4.3% | +23.0% | -8.7% |
| Aug 18 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $0.87 | $0.87 | -0.0% | +8.5% | -5.4% | +17.6% | +4.8% | +12.7% |
| May 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.89 | $0.89 | +0.5% | -7.4% | -3.1% | -4.0% | +7.0% | -4.5% |
| Apr 29 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $0.89 | $0.87 | -1.9% | +1.6% | +6.5% | -4.3% | -3.4% | -7.4% |
| Apr 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.65 | $0.65 | +0.0% | -5.8% | +8.9% | -3.4% | +10.3% | -2.0% |
| Mar 12 | Citizens Capital Markets | Maintains | Market Outperform → Market Outperform | — | $0.66 | $0.71 | +7.7% | +5.3% | +1.5% | +5.4% | +1.4% | -6.2% |
| Dec 11 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $0.97 | $0.97 | +0.0% | -3.1% | -5.8% | -9.6% | +12.0% | -1.0% |
| Nov 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.27 | $1.25 | -1.6% | -6.3% | +0.0% | -3.4% | -7.8% | -2.8% |
| Oct 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.52 | $1.51 | -0.7% | -1.3% | -4.7% | -7.7% | -9.1% | +3.3% |
| Sep 19 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $2.44 | $2.56 | +4.9% | +4.5% | +0.0% | -7.1% | -7.2% | -5.5% |
| Sep 16 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $2.77 | $2.78 | +0.4% | -6.1% | -5.8% | -0.4% | +4.5% | +0.0% |
| Sep 16 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $2.77 | $2.78 | +0.4% | -6.1% | -5.8% | -0.4% | +4.5% | +0.0% |
| Sep 10 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $4.96 | $4.94 | -0.4% | +8.5% | -7.1% | -3.4% | -42.7% | -6.1% |
| Aug 15 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $5.16 | $5.31 | +2.9% | +11.8% | -9.7% | +12.7% | -10.1% | +1.5% |
| Feb 20 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $4.63 | $4.56 | -1.5% | -10.2% | -9.1% | +2.4% | +2.3% | +3.3% |
| Dec 19 | Morgan Stanley | Downgrade | Equal Weight → Underweight | — | $4.37 | $4.11 | -5.9% | -7.6% | -1.7% | +2.3% | +3.7% | -0.7% |
| Nov 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.95 | $2.96 | +0.3% | +2.0% | -0.3% | +0.7% | -0.3% | +0.0% |
| Oct 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.38 | $2.41 | +1.3% | -2.5% | +3.0% | -10.5% | -1.4% | -1.9% |
| Aug 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.57 | $3.56 | -0.3% | -3.4% | -3.8% | +0.6% | -1.2% | +4.2% |
| Aug 4 | Barclays | Maintains | Equal Weight → Equal Weight | — | $3.61 | $3.71 | +2.8% | +1.7% | +0.0% | -2.7% | -0.3% | +1.7% |
| Aug 4 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $3.61 | $3.71 | +2.8% | +1.7% | +0.0% | -2.7% | -0.3% | +1.7% |
| Mar 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.56 | $6.56 | +0.0% | +2.7% | -0.1% | -11.3% | +1.8% | +6.2% |
| Nov 21 | BofA Securities | Downgrade | Neutral → Underperform | — | $7.44 | $7.06 | -5.1% | -12.2% | -0.6% | +2.8% | +2.2% | -5.9% |
| Nov 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.70 | $7.22 | -6.3% | +1.7% | -5.0% | -12.2% | -0.6% | +2.8% |
| Nov 15 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $7.75 | $7.98 | +3.0% | +0.6% | -1.3% | +1.7% | -5.0% | -12.2% |
| Sep 9 | Morgan Stanley | Downgrade | Overweight → Equal Weight | — | $7.94 | $7.45 | -6.2% | -2.4% | -0.5% | +1.7% | -4.7% | +0.7% |
| Jul 29 | Jefferies | Maintains | Buy → Buy | — | $5.55 | $5.70 | +2.7% | -9.9% | +1.0% | +3.6% | +4.8% | +4.6% |
| May 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.04 | $3.99 | -1.2% | +6.7% | +7.2% | +2.4% | +3.0% | -8.6% |
| Mar 17 | Morgan Stanley | Maintains | Overweight → Overweight | — | $7.75 | $7.78 | +0.4% | +7.9% | +0.8% | -12.6% | +0.9% | -1.5% |
| Mar 15 | BofA Securities | Downgrade | Buy → Neutral | — | $7.75 | $7.37 | -4.9% | -7.7% | +8.4% | +7.9% | +0.8% | -12.6% |
| Feb 28 | Barclays | Downgrade | Overweight → Equal Weight | — | $10.39 | $9.61 | -7.5% | -15.0% | -4.1% | +3.2% | -8.0% | -2.2% |
| Nov 17 | Barclays | Maintains | Overweight → Overweight | — | $16.02 | $15.95 | -0.4% | -2.2% | -7.8% | +0.1% | -5.9% | +5.5% |
| Oct 11 | Morgan Stanley | Upgrade | Equal Weight → Overweight | — | $15.87 | $15.89 | +0.1% | +0.6% | -2.4% | +1.5% | +2.6% | +0.2% |
| Oct 8 | Barclays | Maintains | Overweight → Overweight | — | $17.34 | $17.34 | +0.0% | -8.5% | +0.6% | -2.4% | +1.5% | +2.6% |
| Jul 27 | BofA Securities | Upgrade | Neutral → Buy | — | $33.33 | $35.33 | +6.0% | +4.0% | +0.4% | -5.9% | -2.1% | -1.0% |
| Apr 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $34.59 | $36.36 | +5.1% | +4.7% | -1.8% | +11.1% | +2.5% | +2.4% |
| Mar 17 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $55.85 | $58.66 | +5.0% | +0.8% | -6.6% | +3.9% | +6.8% | -5.3% |
| Dec 16 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $69.92 | $70.22 | +0.4% | +2.7% | +6.4% | -0.5% | +2.2% | +6.3% |
| Nov 12 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $40.10 | $39.65 | -1.1% | +6.1% | +12.5% | +0.0% | +8.1% | +2.3% |
No insider trades available.
8-K
Prelude Therapeutics Incorporated -- 8-K Filing
Jun 10
8-K · 2.02
!! High
Prelude Therapeutics Incorporated -- 8-K 2.02: Earnings Results
May 12
8-K
Prelude Therapeutics Incorporated -- 8-K Filing
Prelude Therapeutics is raising capital through an offering to fund research, clinical development, and working capital needs, extending its cash runway for operations.
Apr 21
8-K
Prelude Therapeutics Incorporated -- 8-K Filing
Prelude Therapeutics' PRT13722 demonstrated superior preclinical efficacy in hormone receptor-positive breast cancer compared to dual inhibitors, showing durable complete tumor regressions as monotherapy at tolerable doses.
Apr 20
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
The appointment of a Chief Medical Officer suggests CLYYF and PRLD are strengthening clinical leadership to advance product development and regulatory strategy, potentially accelerating pipeline progress and reducing execution risk.
Apr 15
8-K
Unknown — 8-K Filing
PRLD's legal opinion confirms securities offering compliance, signaling an imminent registered offering or capital raise that will dilute existing shareholders but provide growth capital.
Mar 12
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Prelude Therapeutics advanced its clinical pipeline with IND clearance for PRT12396, signaling execution progress on strategic programs that could drive near-term catalysts and investor confidence.
Mar 10
8-K · 5.02
!!! Very High
Sana Biotechnology, Inc. -- 8-K 5.02: Executive Change
Sana Biotechnology appointed experienced CFO Piper, previously at Scorpion Therapeutics, as Executive Vice President and Chief Financial Officer, strengthening financial leadership during the company's development stage.
Feb 17
8-K · 7.01
! Medium
Prelude Therapeutics Incorporated -- 8-K 7.01: Regulation FD Disclosure
Prelude Therapeutics gained FDA clearance to initiate Phase 1 testing of PRT12396, a JAK2 inhibitor for myeloproliferative neoplasms, advancing its clinical pipeline and de-risking development efforts.
Feb 3
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 1,230,406 | $4M | New | Mar 2026 |
| 2 | Two Sigma Investments, Lp | 923,626 | $3M | Added | Mar 2026 |
| 3 | Morgan Stanley | 669,832 | $2M | Added | Dec 2025 |
| 4 | Acadian Asset Management Llc | 511,519 | $2M | Reduced | Mar 2026 |
| 5 | Millennium Management | 382,737 | $1M | Added | Mar 2026 |
| 6 | Marshall Wace, Llp | 358,906 | $1M | Added | Mar 2026 |
| 7 | Renaissance Technologies Llc | 275,200 | $941K | Added | Mar 2026 |
| 8 | Susquehanna International Group, Llp | 267,788 | $916K | Added | Mar 2026 |
| 9 | Adar1 Capital Management, Llc | 152,825 | $523K | New | Mar 2026 |
| 10 | Citadel Advisors Llc | 124,378 | $425K | New | Mar 2026 |
| 11 | Jane Street Group, Llc | 111,040 | $322K | Added | Dec 2025 |
| 12 | Ubs Group Ag | 64,505 | $221K | Added | Mar 2026 |
| 13 | Hrt Financial Lp | 58,699 | $200K | New | Mar 2026 |
| 14 | Bank Of America Corp /de/ | 56,525 | $193K | Added | Mar 2026 |
| 15 | Northern Trust Corp | 50,120 | $171K | — | Mar 2026 |
| 16 | Focus Partners Wealth | 50,007 | $171K | — | Mar 2026 |
| 17 | Connor, Clark & Lunn Investment Management Ltd. | 46,090 | $134K | New | Dec 2025 |
| 18 | Prudential Financial Inc | 17,420 | $60K | Added | Mar 2026 |
| 19 | Qube Research & Technologies Ltd | 16,417 | $56K | Reduced | Mar 2026 |
| 20 | Point72 Asset Management | 16,329 | $56K | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 9
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 130,651 | $361K | Feb 2026 |
| 2 | Ultra-Small Company Market Fund | 50,000 | $171K | Mar 2026 |
| 3 | Fidelity Total Market Index Fund | 43,616 | $120K | Feb 2026 |
| 4 | Fidelity Series Total Market Index Fund | 35,813 | $99K | Feb 2026 |
| 5 | Fidelity Nasdaq Composite Index Fund | 20,595 | $57K | Feb 2026 |
| 6 | Avantis U.S. Small Cap Equity ETF | 10,294 | $28K | Feb 2026 |
| 7 | U.S. CORE EQUITY 1 PORTFOLIO | 4,982 | $9K | Jan 2026 |
| 8 | Knights of Columbus U.S. ALL CAP INDEX FUND | 153 | $283 | Jan 2026 |
| 9 | Guggenheim Active Allocation Fund | 64 | $177 | Feb 2026 |
Valuation
Market Cap
$332.5M
Enterprise Value
$244.3M
P/E (TTM)
-3.35x
Forward P/E
—
PEG Ratio
0.10x
P/B
4.84x
P/S
27.38x
P/FCF
-5.90x
EV/EBITDA
—
Shares Out
77.0M
Financials (TTM)
Revenue
$12.1M
Net Income
-$99.5M
EBITDA
-$102.9M
Free Cash Flow
-$56.4M
Op Cash Flow
-$56.3M
EPS Basic
$-1.29
EPS Diluted
$-1.29
EPS Forward
$-0.78
Gross Margin
85.9%
Op Margin
-861.3%
Net Margin
-819.6%
Balance Sheet
Total Assets
$141.3M
Total Liab.
$72.7M
Total Equity
$68.6M
Cash
$103.2M
LT Debt
$15.0M
Book Value/Sh
$0.89
Debt/Equity
0.26x
Current Ratio
1.99
Quick Ratio
1.99
Returns & Growth
ROE
-145.0%
ROA
-70.4%
ROIC
-114.8%
Rev Growth YoY
+73.4%
EPS Growth YoY
+23.2%
Price Returns
2W
-12.3%
1M
-25.0%
3M
+42.0%
6M
+133.3%
12M
+342.5%
Technicals
52W High
$5.52
52W Low
$0.78
50d MA
$4.38
200d MA
$2.65
RSI (14)
58.30
ATR (14)
$0.34
Beta
0.71
Avg Volume
358K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$8.00
High
$8.00
Low
$8.00
Median
$8.00
Data updated apr 26, 2026 8:44pm
· Source: financialmodelingprep.com